Results 221 to 230 of about 179,392 (293)

Obstructive sleep apnoea is associated with accelerated progression of diabetic kidney disease

Diabetic Medicine, EarlyView.
Abstract Aim Persons with type 2 diabetes and diabetic kidney disease (DKD) are at high risk of end‐stage kidney disease or death. We investigated the possible contribution of obstructive sleep apnoea (OSA) to decline in kidney function and renal outcomes.
Sebastian Nielsen, Martin B. Thomsen, Jakob Nyvad, Esben Laugesen, Erik Lerkevang Grove, Per Løgstrup Poulsen, Kent Lodberg Christensen, Mads Vaarby Sørensen, Peder Berg, Niels Henrik Buus   +9 more
wiley   +1 more source

Comparative Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers in Hypertensive Patients With Chronic Kidney Disease: A Systematic Review. [PDF]

Cureus
Mhmndar MA, Singh T, Fatima I, Shehryar A, Zaidi MR, Mairaj M, Khan SM, Kolanu ND, Ahmed S, Kamal A, Rehman A, Quinn M.   +11 more
europepmc   +1 more source

Mast Cells in Acute COVID‐19 Patients

Allergy, EarlyView.
Ilan Zaffran, Hadas Pahima, Eli Ben‐Chetrit, Amir Jarjoui, Ilaria Puxeddu, Carl Zinner, Joana Vitte, Alexandar Tzankov, Francesca Levi‐Schaffer   +8 more
wiley   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Preoperative continuation vs. discontinuation of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on early cognitive function in elderly patients undergoing noncardiac surgery: a randomized controlled trial. [PDF]

Front Aging Neurosci
Wang X, Yan Y, Liu Y, Xu C, Zhuang J, Wang Z.   +5 more
europepmc   +1 more source

Kinin generation by hemodialysis membranes as a possible cause of anaphylactoid reactions [PDF]

, 1994
Fink, Edwin, Lemke, Horst-Dieter, Shimamoto, Kazuaki, Verresen, Luc   +3 more
core  

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. [PDF]

Cochrane Database Syst Rev
Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF.   +4 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source